Feeds:
Posts
Comments

Posts Tagged ‘Bispecific Antibodies for T-Cell Redirection’


CHI’s  Advancing Bispecifics to the Clinic and Immunotherapy and Bispecifics for Oncology Targets, 3 – 4 November 2016, Lisbon, Portugal

Reporter: Aviva Lev-Ari, PhD, RN

 

Registration

https://chidb.com/reg/pge/reg.asp

 

Eighth Annual

Engineering Bispecifics

New Approaches and Platform Refinements

3 – 4 November 2016   |  Lisbon, Portugal

PEGSummitEurope.com

Register

Register Today for

Savings up to €400!

Engineering for T Cell Engagement at Engineering Bispecifics at PEGS Europe

Cambridge Healthtech’s 8th Annual Engineering Bispecifics conference showcases the latest developments in engineering bispecifics for T-cell engagement with presentations from Rinat Pfizer, Covagen, Immunocore and Glenmark. These focus on selection and validation of target antigens, platform development, tailored architecture for novel modes of action, preclinical and clinical manufacturing, IgG isotype and affinity, efficacy and specificity.

Additional presentations on this topic can be heard at the PEGS Europe tracks on Advancing Bispecifics to the Clinic and Immunotherapy (Chugai, Numab, Pfizer, Xencor and Macrogenics and Roche Innovation Centre. German Cancer Research Center).

Session Preview

High Affinity T Cell Receptor-Based Bi-Functional Biologics for Redirected Tumour Killing

Joseph Dukes, Ph.D., Head, Pre-Clinical Biology, Cell Biology, Immunocore

ImmTACs are bi-specific reagents that target tumours via a soluble monocloncal TCR with exceptionally high sensitivity and specificity and redirect host polyclonal T cells via an anti-CD3 antibody fragment. The selection and validation of appropriate target antigens and the testing of ImmTACs for specificity is critical. Using appropriate tumour and primary human cell lines, the in vitro pre-clinical package can be predictive of in vivo clinical observations.

Pfizer’s T-Cell Engaging Full Length Bispecific Antibody Platform: From Bench to NHS

Javier Chaparro-Riggers, Ph.D., Senior Director, Protein Engineering, Rinat Pfizer, Inc.

The recent clinical success of blinatumomab (antiCD19/CD3) spurred the development of a variety of T cell engaging bispecific antibody architectures. Pfizer developed a T cell engaging antibody platform, which allows the formation of full length human IgG1 and IgG2 antibodies in vitro or in vivo. The effect of IgG isotype and affinities of the T cell- and tumor antigen-targeting arm were explored and optimized.

Engineering of CD3 Bispecific FynomAbs

Julian Bertschinger, Ph.D., VP, Janssen R&D, Managing Director, Covagen

ImmTACs are bi-specific reagents that target tumours via a soluble monocloncal TCR with exceptionally high sensitivity and specificity and redirect host polyclonal T cells via an anti-CD3 antibody fragment. The selection and validation of appropriate target antigens and the testing of ImmTACs for specificity is critical. Using appropriate tumour and primary human cell lines, the in vitro pre-clinical package can be predictive of in vivo clinical observations.

Engineering and Manufacturing of Bispecific Antibodies for T-Cell Redirection

Stanislas Blein, Ph.D., Senior Director, Antibody Engineering, Glenmark Pharmaceuticals

Over the past two decades various functional bispecific antibody formats have been designed with only few molecules reaching clinical trials due to an inherent lack of manufacturability. Herein we describe a versatile bispecific antibody format that fits industrial-scale manufacturing processes and enables the rapid design and making of T-cell redirecting molecules. Engineering, pre-clinical and phase-one manufacturing data will be presented.

Register

[Register Today for Savings up to €400]

Final Agenda  |  Sponsorship & Exhibits |  Present a Poster  |  View Brochure

Short Courses*

DON’T MISS the short course on Engineering of Bispecific Antibodies

To be led by:
Nicolas Fischer, Ph.D., Head, Research, Novimmune SA
Michaela Silacci, Ph.D., Director, Discovery Research, Covagen AG, part of J&J

* separate registration required for short courses

Breakout Discussions

DON’T MISS the in depth Breakout Discussion on Strategy for Engineering and Design of Bispecific TCR-Based Products

To be moderated by:
Julian Bertschinger, Ph.D., VP, Janssen R&D, Managing Director, Covagen

Agenda-At-A-Glance

NEW MODES OF ACTION / T CELL ENGAGEMENT

KEYNOTE PRESENTATION: Protein Engineering for New Modes of Action

Andreas Plückthun, Ph.D., Director and Professor, Biochemistry, University of Zurich

Pfizer’s T Cell Engaging Full Length Bispecific Antibody Platform: From Bench to NHS

Javier Chaparro-Riggers, Ph.D., Senior Director, Protein Engineering, Rinat Pfizer, Inc.

Presentation to be Announced

Sponsored by Schrödinger

ENGINEERING BISPECIFICS FOR T CELL ENGAGEMENT

Engineering of CD3 Bispecific FynomAbs

Julian Bertschinger, Ph.D., Vice President, Janssen R&D, Managing Director, Covagen


High Affinity T Cell Receptor-Based Bifunctional Biologics for Redirected Tumour Killing

Joseph Dukes, Ph.D., Head, Pre-Clinical Biology, Cell Biology, Immunocore

FOCUS ON BISPECIFIC ENGINEERING FOR TARGETING

Epitopes Matter: Strategies to Generate and Analyse Binders to Different Epitopes

Jonas Schaefer, Ph.D., Head, High-Throughput Binder Selection Facility, Biochemistry, University of Zurich

Engineered Fab Domains Promote Efficient Production of Bispecific Antibodies in a Single Cell

Christoph Spiess, Ph.D., Senior Scientist, Antibody Engineering, Genentech, Inc.


A Novel Highly Versatile Multi-Specific Antibody Format

David Urech, Ph.D., CSO and Co-CEO, Numab AG

PLATFORM DEVELOPMENT AND REFINEMENT

CrossMAb Version 2: A Versatile Toolbox for Bispecific Antibody Engineering
Joerg Thomas Regula, Ph.D., Head, Functional Characterisation, Large Molecule Research, Roche Pharmaceutical Research and Early Development

Efficient Generation of Bispecific Mouse Antibodies for Preclinical Investigations

Aran F. Labrijn, Ph.D., Principal Scientist, Antibody Sciences, Genmab BV

Platform Refinements for Bispecifics for Oncology Targets

John de Kruif, Ph.D., CTO, Merus

Sponsored Presentation (Opportunities Available)

NOVEL APPROACHES

Using Alphabodies to Generate Bispecifics with Optimal in vitro and in vivo Characteristics

Yvonne McGrath, Ph.D., CSO, Complix NV

Hapten-Bispecific Antibodies for Drug Discovery and Delivery Applications

Ulrich Brinkmann, Ph.D., Expert Scientist, Roche Innovation Center

Cellular FRET Assay for the Determination of Simultaneous Binding of Bispecific Antibodies

Stefan Seeber, Ph.D., Principal Scientist, Cell Line and Molecule Development, Roche Innovation Center Munich/Large Molecule Research

Novel Strategy for a Bispecific Antibody: Induction of Dual Target Internalisation and Degradation

Ji Min Lee, Ph.D., Principal Scientist, Open Innovation Team, Samsung Bioepis

Engineering and Manufacturing of Bispecific Antibodies for T-Cell Redirection

Stanislas Blein, Ph.D., Senior Director, Antibody Engineering, Glenmark Pharmaceuticals

Event-at-a-Glance

SOURCE

From: Bispecific Antibodies <katiev@pegsummiteurope.com>

Date: Tuesday, July 12, 2016 at 9:22 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Latest T-Cell Engagement Research from Pfizer, Covagen, Immunocore & Glenmark

Read Full Post »